170 related articles for article (PubMed ID: 24133589)
1. Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer.
Yun F; Jia Y; Li X; Yuan L; Sun Q; Yu H; Shi L; Yuan H
Int J Clin Exp Pathol; 2013; 6(10):2112-20. PubMed ID: 24133589
[TBL] [Abstract][Full Text] [Related]
2. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
4. MiR-4299 suppresses non-small cell lung cancer cell proliferation, migration and invasion through modulating PTEN/AKT/PI3K pathway.
Yang WB; Zhang WP; Shi JL; Wang JW
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3408-3414. PubMed ID: 29917192
[TBL] [Abstract][Full Text] [Related]
5. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
[TBL] [Abstract][Full Text] [Related]
6. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.
Al-Saad S; Donnem T; Al-Shibli K; Persson M; Bremnes RM; Busund LT
Anticancer Res; 2009 Oct; 29(10):4175-83. PubMed ID: 19846969
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.
Shen WM; Yin JN; Xu RJ; Xu DF; Zheng SY
Kaohsiung J Med Sci; 2019 Jul; 35(7):401-407. PubMed ID: 31001918
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
Tang JM; He QY; Guo RX; Chang XJ
Lung Cancer; 2006 Feb; 51(2):181-91. PubMed ID: 16324768
[TBL] [Abstract][Full Text] [Related]
9. Iron Oxide Nanoparticles Synergize with Erlotinib to Suppress Refractory Non-Small Cell Lung Cancer Cell Proliferation Through the Inhibition of ErbB/PI3K/AKT and PTEN Activation.
Zhang M; Sai B; Cao P; Li Z; Zhang L; Shuai C; Wang X; Wang J; Li G; Xiang J; Tang J
J Biomed Nanotechnol; 2017 Apr; 13(4):458-68. PubMed ID: 29388752
[TBL] [Abstract][Full Text] [Related]
10. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
Wang L; Dong X; Ren Y; Luo J; Liu P; Su D; Yang X
Cell Death Dis; 2018 Jan; 9(2):129. PubMed ID: 29374157
[TBL] [Abstract][Full Text] [Related]
11. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer.
Hu J; Liu YL; Piao SL; Yang DD; Yang YM; Cai L
Lung Cancer; 2012 Sep; 77(3):593-9. PubMed ID: 22717106
[TBL] [Abstract][Full Text] [Related]
12. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
[TBL] [Abstract][Full Text] [Related]
13. Long Noncoding RNA FAL1 Promotes Cell Proliferation, Invasion and Epithelial-Mesenchymal Transition Through the PTEN/AKT Signaling Axis in Non-Small Cell Lung Cancer.
Pan C; Yao G; Liu B; Ma T; Xia Y; Wei K; Wang J; Xu J; Chen L; Chen Y
Cell Physiol Biochem; 2017; 43(1):339-352. PubMed ID: 28854421
[TBL] [Abstract][Full Text] [Related]
14. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Stjernström A; Karlsson C; Fernandez OJ; Söderkvist P; Karlsson MG; Thunell LK
Cancer Med; 2014 Apr; 3(2):337-48. PubMed ID: 24500884
[TBL] [Abstract][Full Text] [Related]
15. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.
Cai J; Fang L; Huang Y; Li R; Yuan J; Yang Y; Zhu X; Chen B; Wu J; Li M
Cancer Res; 2013 Sep; 73(17):5402-15. PubMed ID: 23856247
[TBL] [Abstract][Full Text] [Related]
16. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
[TBL] [Abstract][Full Text] [Related]
17. [Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer].
Liao DW; Wang L; Zhang XG; Liu MQ
Ai Zheng; 2006 Oct; 25(10):1238-42. PubMed ID: 17059767
[TBL] [Abstract][Full Text] [Related]
18. Tumour suppressor PTEN enhanced enzyme activity of GPx, SOD and catalase by suppression of PI3K/AKT pathway in non-small cell lung cancer cell lines.
Akca H; Demiray A; Aslan M; Acikbas I; Tokgun O
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):539-44. PubMed ID: 22299584
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of tripartite motif containing 26 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.
Tao JL; Luo M; Sun H; Zhao HM; Sun QS; Huang ZM
Kaohsiung J Med Sci; 2020 Jun; 36(6):417-422. PubMed ID: 32052576
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Significance and Mechanism of PI3K p110β Overexpression
in Non-small Cell Lung Cancer].
Xiong Y; Qu L; Li D; Wang Y; Li T
Zhongguo Fei Ai Za Zhi; 2017 Dec; 20(12):808-816. PubMed ID: 29277178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
